{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:10:04Z","timestamp":1768569004057,"version":"3.49.0"},"posted":{"date-parts":[[2024,12,6]]},"group-title":"Neurology","reference-count":75,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>INTRODUCTION<\/jats:title>\n                  <jats:p>\n                    Adults with Down syndrome demonstrate striatum-first amyloid accumulation with [\n                    <jats:sup>11<\/jats:sup>\n                    C]PiB PET imaging, which has not been replicated with [\n                    <jats:sup>18<\/jats:sup>\n                    F]florbetapir (FBP). Early striatal accumulation has not been temporally quantified with respect to global cortical measures.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Longitudinal PiB (n=175 participants) and FBP (n=92 participants) data from the Alzheimer Biomarkers Consortium-Down Syndrome were used to measure cortical and striatal binding. Generalized temporal models for cortical and striatal amyloid accumulation were created using the sampled iterative local approximation (SILA) method.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>PiB demonstrated greater striatal-to-cortical ratios than FBP. SILA analysis revealed striatal amyloid burden occurs 3.40 (2.39) years earlier than the cortex in PiB. There was no difference between the cortex and striatum in FBP.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>DISCUSSION<\/jats:title>\n                  <jats:p>Among adults with Down syndrome, the striatum consistently accumulates amyloid earlier than the cortex when measured with PiB. This suggests the striatum is more sensitive to the onset of PiB PET-detectable amyloid in Down syndrome.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.12.04.24318526","type":"posted-content","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T19:20:42Z","timestamp":1733512842000},"source":"Crossref","is-referenced-by-count":1,"title":["The striatum is an early, accurate indicator of amyloid burden using [\n                  <sup>11<\/sup>\n                  C]PiB in Down syndrome: comparison of two radiotracers"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-7233","authenticated-orcid":false,"given":"Max","family":"McLachlan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brecca","family":"Bettcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McVea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"DiFillipo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Zammit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisette","family":"LeMerise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Rouanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Tudorascu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Laymon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Keator","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M.","family":"Brickman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Fryer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigan","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beau M.","family":"Ances","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sterling","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobey","family":"Betthauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles K.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Handen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Head","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Mapstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley T.","family":"Christian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024120905560420000_2024.12.04.24318526v1.1","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12390"},{"key":"2024120905560420000_2024.12.04.24318526v1.2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-160836","article-title":"Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer\u2019s Disease: The role of APP","volume":"56","year":"2017","journal-title":"J. Alzheimers Dis. JAD"},{"key":"2024120905560420000_2024.12.04.24318526v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/0047-6374(88)90041-3"},{"key":"2024120905560420000_2024.12.04.24318526v1.4","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","article-title":"Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study","volume":"395","year":"2020","journal-title":"Lancet Lond. Engl"},{"key":"2024120905560420000_2024.12.04.24318526v1.5","first-page":"152","article-title":"Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years","volume":"76","year":"2018","journal-title":"JAMA Neurol"},{"key":"2024120905560420000_2024.12.04.24318526v1.6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01858-9"},{"key":"2024120905560420000_2024.12.04.24318526v1.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"2024120905560420000_2024.12.04.24318526v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2024120905560420000_2024.12.04.24318526v1.9","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","year":"2022","journal-title":"J. Prev. Alzheimers Dis"},{"key":"2024120905560420000_2024.12.04.24318526v1.10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11910-022-01235-1","article-title":"Vascular Considerations for Amyloid Immunotherapy","volume":"22","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"2024120905560420000_2024.12.04.24318526v1.11","doi-asserted-by":"crossref","first-page":"102281","DOI":"10.1016\/j.arr.2024.102281","article-title":"Alzheimer\u2019s drugs, APPlication for Down syndrome?","volume":"96","year":"2024","journal-title":"Ageing Res. Rev"},{"key":"2024120905560420000_2024.12.04.24318526v1.12","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1001\/jama.2023.22924","article-title":"Down Syndrome in a New Era for Alzheimer Disease","volume":"330","year":"2023","journal-title":"JAMA"},{"key":"2024120905560420000_2024.12.04.24318526v1.13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.trci.2018.10.006","article-title":"Alzheimer\u2019s disease in Down syndrome: An overlooked population for prevention trials","volume":"4","year":"2018","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv"},{"key":"2024120905560420000_2024.12.04.24318526v1.14","first-page":"e12065","article-title":"The Alzheimer\u2019s Biomarker Consortium-Down Syndrome: Rationale and methodology","volume":"12","year":"2020","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit"},{"key":"2024120905560420000_2024.12.04.24318526v1.15","unstructured":"Rafii, M. Alzheimer\u2019s Clinical Trial Consortium for Down Syndrome (ACTC-DS) Trial-Ready Cohort - Down Syndrome (TRC-DS). https:\/\/clinicaltrials.gov\/study\/NCT04165109 (2024)."},{"key":"2024120905560420000_2024.12.04.24318526v1.16","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/alz.13778","article-title":"Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2024120905560420000_2024.12.04.24318526v1.17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","year":"2011","journal-title":"Alzheimers Dement. J. Alzheimers Assoc"},{"key":"2024120905560420000_2024.12.04.24318526v1.18","first-page":"48","article-title":"Integrating Biomarker Outcomes into Clinical Trials for Alzheimer\u2019s Disease in Down Syndrome","volume":"8","year":"2021","journal-title":"J. Prev. Alzheimers Dis"},{"key":"2024120905560420000_2024.12.04.24318526v1.19","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0730-07.2007"},{"key":"2024120905560420000_2024.12.04.24318526v1.20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","article-title":"Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer disease: a longitudinal study","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"key":"2024120905560420000_2024.12.04.24318526v1.21","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn107"},{"key":"2024120905560420000_2024.12.04.24318526v1.22","doi-asserted-by":"crossref","first-page":"732159","DOI":"10.3389\/fnagi.2021.732159","article-title":"Prominent Striatum Amyloid Retention in Early-Onset Familial Alzheimer\u2019s Disease With PSEN1 Mutations: A Pilot PET\/MR Study","volume":"13","year":"2021","journal-title":"Front. Aging Neurosci"},{"key":"2024120905560420000_2024.12.04.24318526v1.23","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.285"},{"key":"2024120905560420000_2024.12.04.24318526v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.117728"},{"key":"2024120905560420000_2024.12.04.24318526v1.25","first-page":"1","article-title":"Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population","volume":"9","year":"2017","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit"},{"key":"2024120905560420000_2024.12.04.24318526v1.26","first-page":"171","article-title":"Comparison of longitudinal A\u03b2 in non-demented elderly and Down syndrome","volume":"73","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"2024120905560420000_2024.12.04.24318526v1.27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jalz.2018.01.002","article-title":"Early Striatal Amyloid Deposition Distinguishes Down Syndrome and Autosomal Dominant AD from Late Onset Amyloid Deposition","volume":"14","year":"2018","journal-title":"Alzheimers Dement. J. Alzheimers Assoc"},{"key":"2024120905560420000_2024.12.04.24318526v1.28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(22)00408-2","article-title":"Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer\u2019s disease: a cross-sectional study","volume":"22","year":"2023","journal-title":"Lancet Neurol"},{"key":"2024120905560420000_2024.12.04.24318526v1.29","first-page":"e12020","article-title":"Amyloid accumulation in Down syndrome measured with amyloid load","volume":"12","year":"2020","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit"},{"key":"2024120905560420000_2024.12.04.24318526v1.30","first-page":"1","article-title":"The Centiloid Project: Standardizing Quantitative Amyloid Plaque Estimation by PET","volume":"11","year":"2014","journal-title":"Alzheimers Dement. J. Alzheimers Assoc"},{"key":"2024120905560420000_2024.12.04.24318526v1.31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jalz.2015.05.013","article-title":"The effects of normal aging on amyloid-\u03b2 deposition in nondemented adults with Down syndrome as imaged by [11C]PiB","volume":"12","year":"2016","journal-title":"Alzheimers Dement. J. Alzheimers Assoc"},{"key":"2024120905560420000_2024.12.04.24318526v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.07.490"},{"key":"2024120905560420000_2024.12.04.24318526v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2009.08.016"},{"key":"2024120905560420000_2024.12.04.24318526v1.34","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jalz.2015.01.006","article-title":"Florbetapir PET, FDG PET, and MRI in Down Syndrome Individuals with and without Alzheimer\u2019s Dementia","volume":"11","year":"2015","journal-title":"Alzheimers Dement. J. Alzheimers Assoc"},{"key":"2024120905560420000_2024.12.04.24318526v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1474"},{"key":"2024120905560420000_2024.12.04.24318526v1.36","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.535"},{"key":"2024120905560420000_2024.12.04.24318526v1.37","first-page":"e12013","article-title":"Down syndrome: Distribution of brain amyloid in mild cognitive impairment","volume":"12","year":"2020","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit"},{"key":"2024120905560420000_2024.12.04.24318526v1.38","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00259-023-06209-0","article-title":"Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2\/3 clinical trial of anti-amyloid-\u03b2 monoclonal antibodies in dominantly inherited Alzheimer disease","volume":"50","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2024120905560420000_2024.12.04.24318526v1.39","doi-asserted-by":"publisher","DOI":"10.1101\/235440"},{"key":"2024120905560420000_2024.12.04.24318526v1.40","first-page":"e12126","article-title":"Brain amyloid and the transition to dementia in Down syndrome","volume":"12","year":"2020","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit"},{"key":"2024120905560420000_2024.12.04.24318526v1.41","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac213"},{"key":"2024120905560420000_2024.12.04.24318526v1.42","first-page":"388","article-title":"Characterizing the emergence of amyloid and tau burden in Down syndrome","volume":"20","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2024120905560420000_2024.12.04.24318526v1.43","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"2024120905560420000_2024.12.04.24318526v1.44","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.149732"},{"key":"2024120905560420000_2024.12.04.24318526v1.45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.148981"},{"key":"2024120905560420000_2024.12.04.24318526v1.46","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00836-1"},{"key":"2024120905560420000_2024.12.04.24318526v1.47","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02342-y"},{"key":"2024120905560420000_2024.12.04.24318526v1.48","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1146"},{"key":"2024120905560420000_2024.12.04.24318526v1.49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jalz.2016.08.006","article-title":"Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer\u2019s disease","volume":"13","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2024120905560420000_2024.12.04.24318526v1.50","first-page":"153","article-title":"Histopathological studies on senile plaques in brains of patients with Down\u2019s syndrome","volume":"36","year":"1990","journal-title":"Kobe J. Med. Sci"},{"key":"2024120905560420000_2024.12.04.24318526v1.51","first-page":"330","article-title":"Age-associated development of diffuse and thioflavine-S-positive plaques in Down syndrome","volume":"7","year":"1994","journal-title":"Dev. Brain Dysfunct"},{"key":"2024120905560420000_2024.12.04.24318526v1.52","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1996.0003"},{"key":"2024120905560420000_2024.12.04.24318526v1.53","first-page":"115","article-title":"Diffuse plaques in the cerebellum and corpus striatum in Down\u2019s syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43)","volume":"5","year":"1996","journal-title":"Neurodegener. J. Neurodegener. Disord. Neuroprotection Neuroregeneration"},{"key":"2024120905560420000_2024.12.04.24318526v1.54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00401-020-02175-1","article-title":"Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-\u03b2 plaques in Alzheimer\u2019s disease","volume":"140","year":"2020","journal-title":"Acta Neuropathol. (Berl"},{"key":"2024120905560420000_2024.12.04.24318526v1.55","first-page":"210","article-title":"Pittsburgh Compound-B (PiB) binds amyloid \u03b2-protein protofibrils","volume":"140","year":"2016","journal-title":"J. Neurochem"},{"key":"2024120905560420000_2024.12.04.24318526v1.56","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e31821300bc"},{"key":"2024120905560420000_2024.12.04.24318526v1.57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3233\/JAD-170762","article-title":"Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of A\u03b2 42 but not A\u03b2 40","volume":"61","year":"2018","journal-title":"J. Alzheimers Dis"},{"key":"2024120905560420000_2024.12.04.24318526v1.58","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/dneu.22713","article-title":"Neuropathological correlates of amyloid PET imaging in Down syndrome","volume":"79","year":"2019","journal-title":"Dev. Neurobiol"},{"key":"2024120905560420000_2024.12.04.24318526v1.59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40478-018-0559-4","article-title":"The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer\u2019s disease in individuals with Down syndrome","volume":"6","year":"2018","journal-title":"Acta Neuropathol. Commun"},{"key":"2024120905560420000_2024.12.04.24318526v1.60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1988.tb02018.x"},{"key":"2024120905560420000_2024.12.04.24318526v1.61","doi-asserted-by":"publisher","DOI":"10.1038\/nm0196-93"},{"key":"2024120905560420000_2024.12.04.24318526v1.62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-022-01356-1","article-title":"The amyloid plaque proteome in early onset Alzheimer\u2019s disease and Down syndrome","volume":"10","year":"2022","journal-title":"Acta Neuropathol. Commun"},{"key":"2024120905560420000_2024.12.04.24318526v1.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2021.103641"},{"key":"2024120905560420000_2024.12.04.24318526v1.64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.freeradbiomed.2017.09.013","article-title":"Down syndrome, beta-amyloid and neuroimaging","volume":"114","year":"2018","journal-title":"Free Radic. Biol. Med"},{"key":"2024120905560420000_2024.12.04.24318526v1.65","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01249-0)"},{"key":"2024120905560420000_2024.12.04.24318526v1.66","unstructured":"Conway, K. , Skovronsky, D. & Hefti, F. 18F-AV-45, an A\u03b2 amyloid PET imaging ligand, binds protofibrillar A\u03b2 aggregates. in vol. Abs 141.1\/E22 (2009)."},{"key":"2024120905560420000_2024.12.04.24318526v1.67","first-page":"890","article-title":"Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer\u2019s disease","volume":"13","year":"2010","journal-title":"IDrugs Investig. Drugs J"},{"key":"2024120905560420000_2024.12.04.24318526v1.68","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.535"},{"key":"2024120905560420000_2024.12.04.24318526v1.69","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-019-04516-z","article-title":"Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB","volume":"47","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2024120905560420000_2024.12.04.24318526v1.70","first-page":"180","article-title":"Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies","volume":"11","year":"2019","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit"},{"key":"2024120905560420000_2024.12.04.24318526v1.71","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2753-3"},{"key":"2024120905560420000_2024.12.04.24318526v1.72","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1745-9"},{"key":"2024120905560420000_2024.12.04.24318526v1.73","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.neuroimage.2006.12.015","article-title":"Impact of ventricular enlargement on the measurement of metabolic activity in spatially normalized PET","volume":"35","year":"2007","journal-title":"NeuroImage"},{"key":"2024120905560420000_2024.12.04.24318526v1.74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2019.04.010","article-title":"Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers","volume":"81","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"2024120905560420000_2024.12.04.24318526v1.75","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4306\/pi.2017.14.4.521","article-title":"A Case Report of a 37-Year-Old Alzheimer\u2019s Disease Patient with Prominent Striatum Amyloid Retention","volume":"14","year":"2017","journal-title":"Psychiatry Investig"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.12.04.24318526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:22:08Z","timestamp":1768508528000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.12.04.24318526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":75,"URL":"https:\/\/doi.org\/10.1101\/2024.12.04.24318526","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1002\/alz.70141","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,12,6]]},"subtype":"preprint"}}